AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 4 - (NewsRx.com & NewsRx.net) -- NovaScreen Biosciences Corp. has been awarded a 5-year, $12.95 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. National Institutes of Health (NIH).
The contract, "Innate Immune Receptors and Adjuvant Discovery," focuses on establishing a pipeline of new drug candidates that stimulate the natural capacity of the human innate immune system to initiate and sustain appropriate immunological responses. The drug candidates will be selected for their potential to function as new and improved adjuvants, which are general immune-boosting agents. When combined with specific vaccine antigens, adjuvants can help generate protective immunity against a wide variety of infectious agents, including those that may pose threats to our nation from bioterrorism.
"We are gratified that the NIAID/NIH biodefense program has demonstrated its confidence in our screening and drug discovery capabilities by selecting us to perform this important project," said David M. Manyak, PhD, president and CEO of NovaScreen. "This award will provide NovaScreen with the resources to complete discovery-stage activities and preclinical evaluations of promising compounds that display adjuvant activity. This adjuvant development project is an important component of our drug discovery and development efforts and will build on NovaScreen's broad expertise in receptor pharmacology, high-throughput screening assays, natural product chemistry and in silico drug design."
The innate immune system is the body's first line of defense against infectious micro-organisms. In recent years, a group of ...
Source: HighBeam Research, NIAID awards $12.95 million for biodefense contract.